MetaCap

Glaukos Corporation (GKOS)

NYSE: GKOSHealth CareMedical/Dental InstrumentsUSD

237.31-0.79 (-0.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GKOS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$14.05B
EPS (TTM)
-$2.95
52-week range
93.96 – 255.19
Day range
233.40 – 244.55
Volume / Avg
1.09M / 1.19M
Beta
—

52-week range

$93.96$255.19

GKOS stock today

Shares of Glaukos (GKOS) finished lower on Nov 20 at $237.31, a drop of 0.33% or $0.79 per share, versus the S&P 500's 3.70% decline. At this level, GKOS sits near the top of its 52-week range of $93.96 to $255.19: 7.0% below the high, set on Nov 4, 2026 and 152.6% above the low. GKOS is up 110.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 138.2%.

Glaukos has posted a net loss over the last twelve months (EPS of -$2.95), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Glaukos

Company profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Industry
Medical/Dental Instruments
CEO
Mr. Thomas William Burns
Headquarters
Aliso Viejo, CA
Employees
1,094
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Glaukos generated $507.4 million in revenue, up 32.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Glaukos reported a net loss of $187.7 million, compared with a loss of $146.4 million a year earlier. Gross margin was 55.7% (down from 75.5%) and operating margin -39.3%.

Glaukos annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$507.44M$383.48M$314.71M$282.86M$294.01M
Growth+32.33%+21.85%+11.26%-3.79%+30.70%
Net income$-187.69M$-146.37M$-134.66M$-99.19M$-49.59M
EPS (diluted)$-3.28$-2.77$-2.78$-2.09$-1.07

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$243.85+2.76%

  • Strong buy 3
  • Buy 9
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $225.00High $270.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$0.03 vs $-0.12
Surprise
+125.00%

GKOS news

All GKOS news

Glaukos peers

Health Care sector
GKOS peer companies
CompanyPrice% ChgMarket capCompare
SOLVSolventum Corporation84.50-1.52%$14.36Bvs GKOS
BAXBaxter International Inc.25.390.00%$13.14Bvs GKOS
PENPenumbra Inc.319.12-0.28%$12.58Bvs GKOS
PODDInsulet Corporation133.17-2.96%$9.24Bvs GKOS
GMEDGlobus Medical Inc. Class A66.89-2.49%$8.86Bvs GKOS
TFXTeleflex Incorporated161.58-1.11%$6.41Bvs GKOS
HAEHaemonetics Corporation120.16-0.17%$5.47Bvs GKOS
MMSIMerit Medical Systems Inc.84.34-0.08%$5.05Bvs GKOS

Indexes, lists and sector

Glaukos stock FAQ

What is Glaukos's stock price today?

GKOS last traded at $237.31 as of Nov 20, 4:00 PM EST, down 0.33% on the day. Prices are delayed at least 15 minutes.

Who is Glaukos's CEO?

Mr. Thomas William Burns is the chief executive officer of Glaukos Corporation, which has about 1,094 employees.

What is the GKOS 52-week high?

The 52-week high for GKOS is $255.19 and the 52-week low is $93.96. The stock is currently 7.0% below its high.

Compare GKOS